Oil prices hold sharp losses with focus on secondary India tariffs
NEW YORK -Shares of Chemours Co (NYSE:CC) gained 1.01% in pre-market trading on Tuesday after the chemical company reported fourth quarter revenue that beat analyst expectations, though earnings fell slightly short.
Chemours posted Q4 revenue of $1.4 billion, surpassing the consensus estimate of $1.37 billion. However, adjusted earnings per share came in at $0.11, missing analysts' forecasts of $0.12.
For the full year 2024, Chemours reported net income of $86 million, or $0.57 per diluted share, compared to a net loss of $238 million, or $1.60 per share, in 2023. Annual revenue declined 5% to $5.8 billion.
Looking ahead, the company expects 2025 adjusted EBITDA between $825 million and $975 million. Chemours also anticipates capital expenditures of $250 million to $300 million for 2025.
"We are well underway executing our Pathway to Thrive strategy, as evidenced by our recent strong performance," said Denise Dignam, Chemours President and CEO. "While 2024 was a year of transition for Chemours, with a refreshed management team and strategy, we have the right pieces in place to move forward."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.